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GlycosylationPrimary carnitine deﬁciency is causedby impaired activity of theNa+-dependentOCTN2 carnitine/organic cation
transporter. Carnitine is essential for entry of long-chain fatty acids into mitochondria and its deﬁciency impairs
fatty acid oxidation. Most missense mutations identiﬁed in patients with primary carnitine deﬁciency affect
putative transmembrane or intracellular domains of the transporter. Exceptions are the substitutions P46S and
R83L located in an extracellular loop close to putative glycosylation sites (N57, N64, andN91) ofOCTN2. P46S and
R83L impairedglycosylation andmaturationofOCTN2 transporters to theplasmamembrane.We testedwhether
glycosylation was essential for the maturation of OCTN2 transporters to the plasma membrane. Substitution of
each of the three asparagine (N) glycosylation sites with glutamine (Q) decreased carnitine transport.
Substitution of two sites at a time caused a further decline in carnitine transport thatwas fully abolishedwhen all
three glycosylation sites were substituted by glutamine (N57Q/N64Q/N91Q). Kinetic analysis of carnitine and
sodium-stimulated carnitine transport indicated that all substitutions decreased theVmax for carnitine transport,
but N64Q/N91Q also signiﬁcantly increased the Km toward carnitine, indicating that these two substitutions
affected regionsof the transporter important for substrate recognition.Westernblot analysis conﬁrmed increased
mobility of OCTN2 transporters with progressive substitutions of asparagines 57, 64 and/or 91 with glutamine.
Confocal microscopy indicated that glutamine substitutions caused progressive retention of OCTN2 transporters
in the cytoplasm, up to full retention (such as that observed with R83L) when all three glycosylation sites were
substituted. Tunicamycin prevented OCTN2 glycosylation, but it did not impair maturation to the plasma
membrane. These results indicate that OCTN2 is physiologically glycosylated and that the P46S and R83L
substitutions impair this process. Glycosylation does not affect maturation of OCTN2 transporters to the plasma
membrane, but the 3 asparagines that are normally glycosylated are located in a region important for substrate
recognition and turnover rate.Departments of Pediatrics and
ario Capecchi Drive, Salt Lake
1 587 7690.
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Primary carnitine deﬁciency (OMIM #212140) is a recessively
inherited disorder of the carnitine cycle that impairs fatty acid oxidation
[1]. Carnitine is essential for entry of long-chain fatty acids into
mitochondria to allow subsequent β-oxidation [1]. Carnitine deﬁciency
can result in fasting-induced hypoketotic hypoglycemia, hepatic enceph-
alopathy, sudden death, skeletal or cardiac myopathy [2]. The gene for
primary carnitine deﬁciency, SLC22A5, encodes the carnitine transporter
OCTN2 [3,4]. Heterogeneous mutations have been identiﬁed in affected
patients (reviewed in refs. [1,5]). OCTN2 is a novel organic cation
transporter and operates a sodium-dependent transport of carnitine
[3,4,6] and a sodium-independent uptake of organic cations [6–9].The OCTN2 carnitine transporter is composed of 557 amino acids
with 12 predicted transmembrane spanning domains [3,4]. As for
other organic cation transporters, both the amino and carboxy
terminus are predicted to face the cytoplasm [3,4]. The study of
natural mutations and chimeric transporters obtained by fusing
speciﬁc domains of the OCTN2 transporter with the OCTN1 trans-
porter (that does not transport carnitine) has identiﬁed multiple
domains of OCTN2 essential for function. The C-terminus of OCTN2 is
required for an efﬁcient transmembrane transfer of the Na+/carnitine
complex with an essential role played by tyrosine residues in the
intracellular loop between transmembrane domains 10 and 11
[10,11]. The N-terminus and residues in transmembrane domains 7,
9 and 10 have important roles in carnitine recognition [11]. Other
mutations such as S467C and P478L in transmembrane domain 11 can
impair carnitine transport without affecting cation transfer [8,9].
All organic anion transporters (OATs) and cation organic transport-
ers (OCTs) encoded by the SLC22 family share a large extracellular loop
between transmembrane domains 1 and 2 [12]. The structure of this
loop is highly conserved among OCT family members suggesting an
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contains two to ﬁve putative glycosylation sites, depending on the
speciﬁc transporter [12]. Substitution of asparagines with glutamines at
N-glycosylation sites of the human organic anion transporter 1 (hOAT1)
indicated that one speciﬁc residue (N39) plays an important role in
substrate recognition,while other residues couldbe substitutedwithout
compromising transporter function [13]. However, simultaneous
replacement of all glycosylation sites impaired maturation of the
organic anion transporter to the plasma membrane and abolished its
function [13]. Similarly, complete inhibition of glycosylation of OAT4
prevents membrane insertion of transporters, while inhibition of
speciﬁc glycosylation steps results in defective transporters with
decreased afﬁnity towards the substrate [14]. In the organic cation
transporter 2 (OCT2), substitution of all glycosylation sites retains
transporters in the cytoplasm, while substitution of single sites
decreases the transporter turnover rate, but can increase afﬁnity
towards the substrate [15].
The OCTN2 carnitine transporter contains three putative glycosyl-
ation sites: N57, N64 and N91 [3,4], yet there are no detailed studies on
the effect of glycosylation on OCTN2 function. OCTN2VT, a splice variant
of OCTN2 retaining 24 additional amino acids between residues E131
and W132 in the ﬁrst extracellular loop, has defective glycosylation,
maturation to the plasma membrane and carnitine transport activity
[16]. It is unclear whether the inhibition of glycosylation is directly
related to the failed maturation to the plasma membrane. A single
glycosylationmutant (N91Q)ofOCTN2 reduced transporter abundance,
but retained carnitine transport activity when corrected for the level of
expression [16].
Weandothershave identiﬁed severalmutations in the SLC22A5gene
in patients with primary carnitine deﬁciency [1]. Most substitutions
affect putative intracellular or transmembrane domains of the OCTN2
transporter [1]. However, two of these mutations (P46S and R83L) are
located close to putative glycosylation sites of OCTN2 [2,5]. In this paper
we show that OCTN2 is physiologically glycosylated and study the effect
of natural (P46S and R83L) and artiﬁcial mutations on OCTN2
glycosylation and function.
2. Materials and methods
2.1. Patients
The R83L substitution in the OCTN2 carnitine transporter was
originally found in a patient with primary carnitine deﬁciency identiﬁed
after an episode of severe hypoglycemia and in her asymptomatic sister
[17]. Subsequently, we identiﬁed another homozygousmale patient who
presentedwithhepatic encephalopathy. Thismutationwasalso identiﬁed
in a compound heterozygous state with other mutations (G15W and
A214V) in an infant and hismother (both affectedwith primary carnitine
deﬁciency). The latter were identiﬁed presymptomatically by expanded
newborn screening in the child. Finally, it was found in an unrelated
asymptomaticmother in combinationwithA214V as a result of abnormal
newborn screening in anunaffected (carrier) child. As inmost other cases
of maternal carnitine deﬁciency [5], these mothers had normal physical
examination and no symptoms related to primary carnitine deﬁciency.
The P46S substitution was initially reported in mothers with primary
carnitine deﬁciency identiﬁed by expanded newborn screening in their
child [5]. To date, we have found this substitution in seven mothers and
two children, always in combination with a variety of other mutations
(N32S, A42S/R488H, T232M, R254X, R282X, P398L, and T520fs521X). All
patientswith theP46Smutationswere identiﬁedpresymptomatically and
family studies identiﬁed two additional adults compound heterozygous
with the same substitution (total of nine adults with the P46S
substitution). In our series of patients with primary carnitine deﬁciency,
P46S is the mutation most frequently encountered in asymptomatic or
minimally symptomatic (easy fatigability, muscle pain with exercise,
fasting intolerance) adults.2.2. DNA analysis
DNA studies were approved by the Institutional Review Board of the
University of Utah. Informed consent or parental consent was obtained
prior to all DNA studies. Genomic DNAwas extracted from ﬁbroblasts or
peripheral blood by standard methods and ampliﬁed using PCR and
primers ﬂanking each of the 10 exons of the SLC22A5 gene [2,5]. PCR
products were visualized by agarose gel electrophoresis, puriﬁed by
Qiagen column, and sequenced directly using an ABI automated DNA
sequencer. Mutations were conﬁrmed by sequencing in both directions
in two independent PCR products.
2.3. Cell culture and carnitine transport
Chinese hamster ovary (CHO) cells were grown inHamF12medium
supplemented with 6% fetal bovine serum. Carnitine transport was
measured at 37 °Cwith the cluster-traymethod as described previously
[10,11]. HEK-293 cells were grown in Dulbecco's modiﬁed Eagle's
Medium supplemented with 10% fetal bovine serum. For transport
measurement, cellswere grown to conﬂuence in 24-well plates (Costar)
and depleted of intracellular amino acids by incubation for 90 min in
Earle's balanced salt solution containing 5.5 mM D-glucose and
supplemented with 0.1% bovine serum albumin. Carnitine (0.5 M,
0.5 Ci/ml) was then added to the cells for 30 min. Nonsaturable
carnitine transport was measured in the presence of 2 mM cold
substrate. The transport reaction was stopped by rapidly washing the
cells three times with ice-cold 0.1 M MgCl2. Intracellular carnitine was
extracted from the cells with 0.5 ml of ice-cold ethanol and added to
5 ml of scintillation ﬂuid for counting. Intracellular carnitine was
normalized for the protein content and intracellular water of each
well and expressed as nmol/ml cell water [10,11]. Saturable carnitine
transport was calculated by subtracting transport in the presence of
excess cold substrate from total transport and values are reported as
means±SE of three to six independent determinations. Initial experi-
ments on CHO cells transfected or not with OCTN2 indicated that
carnitine (0.5 μM) accumulation was linear up to 60 min (not shown).
Kinetic constants for carnitine (0.5–100 μM) transport were deter-
mined by nonlinear regression analysis according to a Michaelis–Menten
equation [10,11]. Nonsaturable carnitine transport, measured in the
presence of 2 mMcarnitine, was subtracted from total transport to obtain
saturable carnitine transportprior tononlinear regressionanalysis [10,11].
Carnitine transport in the absence of sodium was measured substituting
methylglucamine for sodium, so that the sum of methylglucamine and
sodium remained constant at 150 mM [18]. Nonlinear parameters are
expressed in the text and ﬁgures as means±SD.
In previous studies, we used multiple carnitine concentrations to
deﬁne the Km of OCTN2 toward sodium (KNa) [18,19]. However, we
noted that the value obtained from the intercept of multiple
regressions was identical to the value obtained at the lowest
concentration of carnitine (0.5 μM; refs. [18,19]). This is because, in a
random bireactant system, such as the carnitine/Na cotransporter, the
apparent Km toward the co-substrate (KNa) approaches the true Km
(KNa) as the concentration of the substrate (carnitine) decreases to
near zero [20]. Since our previous studies indicated experimentally
that a concentration of carnitine of 0.5 μMprovided values of apparent
KNa indistinguishable from those calculated from the intersection of
multiple curves, in this study we used an even lower concentration of
carnitine (0.1 μM) to obtain an apparent KNa that approaches closely
true KNa.
2.4. OCTN2 expression studies
The vector containing the OCTN2 cDNA fused in frame with the
green ﬂuorescent proteinwas previously described [18]. Mutant OCTN2
cDNAs were created by site-directed mutagenesis using the Quick
Change system (Stratagene) following the manufacturer's instructions.
Fig. 1. Carnitine transport in CHO cells expressing normal and mutant carnitine
transporters. CHO cells were transfected with normal and mutant OCTN2 cDNAs and
selected for resistance to G418 (0.8 mg/ml). Carnitine (0.5 μM) transport was measured
for 30 min in stably transfected cells and corrected for nonsaturable uptake (measured in
thepresenceof 2 mMcold carnitine). Points are averages±SEof three toﬁve independent
experiments (each in triplicate). *pb0.01 versus CHO-K1, R83L, N57/64/91Q. **pb0.01
versus P46S and N64/91Q. ***pb0.01 versus OCTN2, N57/64Q, N57/91Q using analysis of
variance.
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mutation and the absence of PCR artifacts. Plasmids were transfected
into CHO cells by lipofectamine according to the manufacturer's
instructions (Invitrogen). Cells were selected with 0.8 mg/ml G418
(Gibco-BRL) for 2 weeks and a mass culture composed of several
independent clones of transfected cells was isolated. HEK 293 cellswere
transiently transfected using calcium chloride with the same vectors
and used 2 days after transfection.
2.5. Western blot analysis
CHO cells stably transfected with normal and mutant OCTN2
transporters were washed twice with phosphate buffered saline
solution (PBS), scraped from plates and re-suspended in homogeniza-
tion buffer (20 mM Tris pH 7.4, 1 mM EDTA, 0.25 M sucrose and
Complete protease inhibitors (Roche)). Cells were homogenized with a
Dounce Teﬂon homogenizer with three strokes of 20 s each on ice.
Homogenates were transferred to centrifuge tubes and centrifuged for
10 min at 500×g to sediment the nuclei fraction. Supernatants were
transferred to clean tubes and centrifuged for 20 min at 5000×g to
removemitochondria. Supernatantswere transferred to clean tubes and
the membrane fractions were sedimented at 38,000×g for 60 min,
followed by a wash in homogenization buffer and re-centrifugation at
38,000×g for 15 min. 20 mg native membrane fractions were solubi-
lized in sample buffer (without boiling) and separated by SDS-PAGE.
Proteins were transferred to Immobilon-P membranes (Millipore) by
semi-dryWestern blot. Membraneswere probedwith a 1:1000dilution
of a rabbit anti-GFP antibody (Invitrogen) followed by a 1:5000 goat
anti-rabbit HRP (Santa Cruz). Immunoreactive bands were visualized
using the ECL plus chemiluminescence kit (Amersham).
Hek293 cells were washed twice with PBS, lysed in lysis buffer
(20 mMTris pH 7.5, 100 mMNaCl, 0.5% NP-40, 0.5 mMEDTA). Samples
(20 μg) were treated with peptide/N-glycosidase F (PNGase F, New
England Biolabs) at 37 °C for 1 h using themanufacturer's protocol with
the exception of omitting the denaturing steps prior to the enzymatic
digest. The treated sampleswere separated on SDS-PAGE and probed as
above.
2.6. Confocal microscopy
Subcellular distribution of normal and mutant OCTN2 carnitine
transporters conjugated with the green ﬂuorescent protein was
analyzed with confocal microscopy (Olympus FVX laser scanning
confocal IX70 microscope using a 60× 1.4NA PLANAPO oil objective).
Cells were seeded on glass-bottomed (No. 0 coverglass) microwell
dishes (P35G-0-14-C, MatTek Corporation, Ashland, MA, USA, www.
mattek.com), coveredwithmediumand evaluated in vivo after labeling
with Bodipy-ceramide (Molecular Probes, Eugene, OR, USA, http://
probes.invitrogen.com/) to visualize the Golgi/endoplasmic reticulum
(ER) in red. Images of the cells were obtained at 1 μm sections. Contrast
microscopy was used on the same cells to deﬁne cell borders and
intracellular structures. Images were then digitally superimposed using
Adobe Photoshop [2]. Multiple cells were scanned and representative
cells are shown.
For quantitative studies, images were analyzed using the Meta-
Morph® Imaging System (Molecular Devices, Sunnyvale, CA). Images
obtained for the green dye (carnitine transporters) were co-localized
with those obtained for the red dye (Golgi/endoplasmic reticulum).
Pixels not co-localizing were expressed as percent of total green pixels.
The data obtained were averaged and analyzed using SigmaPlot.
3. Results
The SLC22A5 gene encoding the OCTN2 carnitine transporter was
sequenced in patients with primary carnitine deﬁciency. The P46S and
R83L substitutions were identiﬁed in several patients (see Patients inExperimental Procedures). Both mutations markedly impaired carni-
tine transport when expressed in CHO cells (Fig. 1), although P46S
retained transport activity signiﬁcantly above that measured in
untransfected CHO cells (pb0.01 using analysis of variance).
Analysis of P46S- and R83L-GFP-tagged transporters by confocal
microscopy indicated that both mutations retained the majority of the
protein in the cytoplasm when expressed in CHO cells (Fig. 2B). The
P46S and R83L substitutions are located close to the three putative
glycosylation sites of OCTN2 (N57, N64 and N91) (Fig. 2A). We tested
whether substitution of these putative glycosylation sites with
glutamine (Q) impaired carnitine transport and membrane localization
of OCTN2. As an added control, we generated an additional mutant,
N133Q, as asparagine 133 is not predicted to be glycosylated. Carnitine
transport decreased signiﬁcantly in CHO cells expressing N57Q, N64Q,
N91Q and N133Q as compared to the normal OCTN2 (Fig. 1). Carnitine
transport decreased further with the simultaneous substitution of two
putative glycosylation sites (N57/64Q, N57/91Q, N64/91Q), with the
N64/91Q double substitution being the most effective in reducing
carnitine transport. The increase in carnitine transport above that
measured in untransfected cells (CHO-K1)was abolishedwhen all three
glycosylation sites were substituted by glutamine (N57/64/91Q)
(Fig. 1).
Westernblot analysis of native proteins (boilingmarkedly decreased
protein reactivity and created multiple artiﬁcial bands) from CHO
lysates indicated that P46S- and R83L-OCTN2 had decreased abundance
and increased mobility as compared to wild-type OCTN2 (Fig. 3A).
Substitution of putative glycosylation sites caused a progressive
increased mobility of the OCTN2 transporter as more asparagines
were substituted by glutamine (Fig. 3A). Although estimation of protein
size on native gels is only approximate, OCTN2 transporters substituted
atmore thanoneglycosylation sitehad anapparentmobility close to the
60 kDa standard (thepredicted size of unglycosylatedOCTN2 is 62,751).
The substitution of glycosylation sites also decreased the intensity of the
OCTN2-GFP signal, that was the most reduced with N64/N91Q double
substitution and with the N57/64/91Q triple substitution in which only
a shadow was seen (Fig. 3A). By contrast, substitution of N133 (not a
glycosylation site) with glutamine did not affect mobility or intensity of
the OCTN2 signal, conﬁrming that this residue is not physiologically
glycosylated.
Glycosylation can be studied with inhibitors or with digestion of
previously glycosylated proteins. Unfortunately, the amount of OCTN2
protein produced by stably transfected CHO cells was not sufﬁcient for
this type of analysis. HEK-293 cells produced increased amounts of
OCTN2 protein after transfection in comparison to CHO cells and were
used for this type of study. Digestion of extracts from HEK-293 cells
overexpressing the OCTN2 carnitine transporter with Peptide/N-
glycosidase F (PNGase) or preincubation with tunicamycin, a glycosyl-
ation inhibitor, reduced the apparent size of the OCTN2 transporter to a
Fig. 2. (A) Schematic of the carnitine transporter with putative glycosylation sites (branching). The natural mutations (P46S and R83L) and the artiﬁcial substitution N133Q are also
shown. Putative function of different domains of the transporter were determined in previous studies [10,11,22]. (B) Subcellular distribution of normal and mutant OCTN2 carnitine
transporters. The wild-type (A), P46S- (B) and R83L-mutant (C) OCTN2 transporters were tagged with the green ﬂuorescent protein and stably expressed in CHO cells. Cells were
labeled in vivo with Bodipy-ceramide to visualize the Golgi. Phase contrast microscopy was used to deﬁne the cell borders and intracellular structures. Images were digitally
overlayed to show the location of green transporters compared to the red Golgi and plasma membrane. Co-localization of membrane transporters with the Golgi is seen as a yellow
signal.
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substitutions (Fig. 3B). No additional size reduction was observed in
extracts from tunicamycin-treated cells that were subsequently treated
with PNGase, indicating that both treatments completely removed all
N-linked glycosylation.
Since P46S- andR83L-mutant carnitine transporters failed tomature
to the plasma membrane, we tested whether glycosylation mutants
were also retained in the cytoplasm (Fig. 4). There was a progressiveFig. 3. Western blot analysis of normal and mutant OCTN2 transporters tagged with GFP. (A
separated by native gel electrophoresis and recognized by an anti-GFP polyclonal antibody
internal control. (B) Cells expressing the normal OCTN2 transporter were preincubated for 24
peptide/N-glycosidase F (PNGase) prior to separation by native gel electrophoresis where iincrease in the retention of OCTN2 transporters in the cytoplasm when
more asparagine glycosylation sites were substituted by glutamine.
N133Q also reduced membrane localization of the OCTN2 transporter.
As shown in Fig. 4, normal OCTN2 transporters reaching the plasma
membrane (green) did not co-localize with markers for the Golgi/
Endoplasmic reticulum (red). For this reason, wemeasured the percent
of total OCTN2 transporters reaching the plasmamembrane as those not
co-localizing with the red signal using MetaMorph. There was a) Cell lysates from CHO cells expressing normal and mutant OCTN2 transporters were
. CHO cells expressing the green ﬂuorescent protein alone (EGFP) were included as an
h in the absence or presence of tunicamycin (1 μg/ml). Cell extracts were digested with
ndicated.
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percent of OCTN2 transporters localized on the plasma membrane
(Fig. 5), indicating that cytoplasmic retentionwas an important factor in
reducing carnitine transport activity by the substitutions evaluated.
Since the N-terminus of the OCTN2 carnitine transporter is
involved in substrate and co-substrate recognition [11], we evaluated
whether the glycosylation mutants affected the kinetic constants for
carnitine transport. All glycosylation substitutions decreased the
Vmax for carnitine transport, the effect being more marked for the
combination N64/91Q (Fig. 6). The N64/91Q substitution also caused a
signiﬁcant (pb0.01 versus OCTN2 using conﬁdence intervals) increase
in the Km toward carnitine, indicating that N64 and N91 may be part
or close to a site important for substrate recognition.
The OCTN2 carnitine transporter is energized by the sodium
electrochemical potential. We previously found that the C-terminus of
OCTN2 is involved in the transfer of theNa/carnitine complex inside the
cell [10,18].Weevaluatedwhether substitutions in theﬁrst extracellular
loop also affected sodium stimulation of carnitine transport. Despite a
marked decline in the amount of carnitine transport that could be
stimulated by sodium, there was no signiﬁcant difference in the
concentration of sodiumatwhichhalf-maximal stimulation of transportFig. 4. Subcellular distribution of normal and mutant carnitine transporters tagged with the
GFPwere seeded on glass-bottomed dishes. Live cells were visualized by confocal microscopy
Phase contrast microscopy was used to deﬁne the cell borders and intracellular structures. I
the red Golgi and plasma membrane. Co-localization of membrane transporters with the Gby sodium was observed (KNa) between the normal OCTN2 and any of
the mutants (Fig. 7).
To determinewhether the structural change of the ﬁrst extracellular
loop caused by the amino acidic substitution, rather than glycosylation
affected transporter activity, carnitine transport was measured after
preincubation of cells with tunicamycin. Tunicamycin effectively
prevented OCTN2 glycosylation (Fig. 3B), but had no effect on carnitine
transport (Fig. 8A) until a toxic effect was observed at about 1 μg/ml as
indicated by decreased amounts of cellular proteins at the end of the
incubation period (Fig. 8B). After preincubation with tunicamycin
(0.5 μg/ml) for 16 h, no signiﬁcant changes in the kinetic parameters for
carnitine transportwere observed in tunicamycin-treated cells (Fig. 8C).
Finally, we checked whether incubation with tunicamycin affected
maturation of the transporters to the plasma membrane. OCTN2
carnitine transporters had normal membrane distribution whether or
not incubated for 16 hwith tunicamycin (0.3–1 μg/ml) (Fig. 9). Analysis
of data with MetaMorph indicated that more than 95% of the green
signal (OCTN2 transporters tagged with GFP) did not co-localize with
the red signal (Golgi and ER stained with Bodipy-ceramide) in cells
treated with tunicamycin 0.3 or 1 μg/ml, a value similar to cells not
exposed to tunicamycin (Fig. 9A).green ﬂuorescent protein. CHO cells stably transfected with normal and mutant OCTN2-
at 1 μm sections. Cells were labeled in vivo with Bodipy-ceramide to visualize the Golgi.
mages were digitally overlayed to show the location of green transporters compared to
olgi is seen as a yellow signal.
Fig. 5. Correlation between carnitine transport and membrane localization of mutant
OCTN2-carnitine transporters. Confocal microscope images were analyzed using the
MetaMorph® Imaging System (Molecular Devices, Sunnyvale, CA). Images obtained for
the green dye (carnitine transporters) were co-localized with those obtained for the red
dye (Golgi/endoplasmic reticulum). Pixels not co-localizing were expressed as percent of
total green pixels. The data obtained were averaged and analyzed using SigmaPlot.
Membrane-localized transporters were then correlated with carnitine transport. The line
represents a linear regression of data. Signiﬁcance of the regression was obtained using
analysis of variance. Points are averages of quadruplicates for imaging and three to ﬁve
samples for transport activity. Standard deviations are indicated in both directions and are
not visible when smaller than the symbol.
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Allmembrane transporters encodedby the SLC22gene family share a
highly conserved large extracellular loop between transmembraneFig. 6. Kinetic analysis of transport by normal andmutant OCTN2. Carnitine (0.5–100 μM) tra
OCTN2 expression vectors. Nonsaturable carnitine transport, measured in the presence of 2 m
Each point is the mean of triplicates±SE. Lines represent the best ﬁt of data to a Michaelis
expressed as means±SD. Two different mass cultures expressing the normal OCTN2 transpdomains 1 and 2 suggesting an essential role of this domain in
transporter function [12]. Very few natural mutations affect this
extracellular loop in patients with primary carnitine deﬁciency, with
the exception of P46S and R83L [1,2]. This loop contains three putative
glycosylation sites in the OCTN2 carnitine transporter (Fig. 2A).
Substitution of each of these asparagine residues with glutamine
reduced carnitine transport (Fig. 1) and affected mobility of the
OCTN2 carnitine transporter (Fig. 3). By contrast, substitution of the
unrelated asparagine 133 did not affect transporter mobility, although
transport activity was still reduced. Protein mobility was further
affectedwhenmultiple siteswere substituted,with the highestmobility
seen when all three sites were mutated (Fig. 3). The mobility of the
OCTN2 transporter with all three asparagine sites substituted was
similar to that of transporters treated with PNGase or to that of cells
treatedwith tunicamycin to prevent glycosylation (Fig. 3). These results
indicate that the OCTN2 carnitine transporter is physiologically
glycosylated at asparagine in positions 57, 64 and 91 and, consequently,
conﬁrm that this loop is located in the extracellular space.
Substitution of asparagine residues with glutamine generally
decreased the abundance of the OCTN2 transporter and caused
progressive retention of transporters in the cytoplasm (Figs. 4 and 5).
Interestingly,mild cytoplasmic retentionofmembrane transporterswas
also seenwith the N133Q substitution, not affecting a glycosylation site.
ThenaturalmutationsP46L andR83L identiﬁed inpatientswithprimary
carnitine deﬁciency decreased transporter abundance, increased trans-
porter mobility to the levels seen when multiple glycosylation sites
were substituted, caused cytoplasmic transporter retention, andnsport wasmeasured for 30 min in CHO cells stably transfected with normal andmutant
M cold carnitine, was subtracted from each point prior to calculating kinetic constants.
–Menten equation. Kinetic parameters, obtained by nonlinear regression analysis, are
orter were evaluated in each experiment and both are shown.
Fig. 7. Sodium stimulation of carnitine transport in CHO cells expressing normal and mutant OCTN2 transporters. Carnitine (0.1 μM) transport was measured for 30 min at the indicated
concentrations of sodium (0–150 mM). Cells werewashed three timeswith a sodium-free solution prior to the transport experiment. Sodium-independent carnitine transport, measured
in the absence of extracellular sodium, was subtracted from all points prior to plotting. Points are averages±SE of triplicates. The data obtained were subjected to nonlinear regression
analysis according to aMichaelis–Menten equation to obtain the concentration of sodiumatwhich half-maximal stimulationwas obtained (KNa, see Section 2). Parameters are reported as
averages±SD. Two different mass cultures expressing the normal OCTN2 transporter were evaluated in each experiment and both are shown.
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mutations induce a conformational change of the OCTN2 transporter
and cause a defect in the maturation to the plasma membrane and in
glycosylation, although we are not sure whether this latter defect is
complete or not. In fact, repeated experiments to determine whether
PNGase affected the mobility of these mutant transporters were
unsuccessful due to their low abundance.
Glycosylation per se had only limited inﬂuence on maturation of
the transporters to the plasma membrane since incubation with
tunicamycin did not affect membrane transport or maturation to the
plasma membrane (Figs. 8 and 9). Since the N133Q substitution also
decreased transport activity, the structural change of the extracellular
loop caused by the amino acid substitution, rather than glycosylation
itself, affected carnitine transport. This also suggests that this large
extracellular loop of the transporter, independently from its glycosyl-
ation status, is important for transporter maturation to the plasma
membrane and overall function.
Evaluation of kinetic constants of the OCTN2 transporter toward
carnitine (Fig. 6) or its co-substrate sodium (Fig. 7) indicated that all
asparagine substitutions tested decreased the Vmax for carnitine
transport (Fig. 6). It is difﬁcult to normalize transporter activity for the
amount of transporter protein (Fig. 3), since the different transporter
structure also resulted in decreased maturation of transporters to the
plasma membrane (Fig. 5). The N133Q substitution and the double
substitution N57Q/N64Q resulted in an abundance of immunoreactive
OCTN2 transporters similar to that seen with the wild-type OCTN2(Fig. 3). Nevertheless, only about 20% of N57/64Q transporters reached
the plasma membrane as compared to 70% of N133Q transporters and
N90% of the wild-type OCTN2 (Fig. 5). This indicates that one of the
major effects of the N133Q substitution was to reduce the unitary
turnover rate (number of molecules transported inside the cell by each
transporter) of the OCTN2 transporter, independently from an effect on
glycosylation (Fig. 3) and with only a limited effect on cytoplasmic
retention (Fig. 5). By contrast, the effect of glycosylation mutants was
more related to the retention of transporters in the cytoplasm, with a
signiﬁcant correlation between the amount of transporters localizing to
the plasma membrane and carnitine transport activity (Fig. 5). The
double mutant N64/91Q that was farther away from the regression line
(Fig. 5) was unique in signiﬁcantly increasing the Km toward carnitine
to about 5 times normal (Fig. 6). None of themutants, however, affected
the recognition of sodiumwith KNa that were not signiﬁcantly different
from that seen in control cells (Fig. 7). These results indicate that
asparagine substitutions affect the unitary turnover rate of the
transporter, maturation of the transporters to the plasma membrane
and that the region around residues 64 and 91 might be involved in
carnitine recognition. This effect on transporter afﬁnity toward the
substrate might explain why the R83L natural substitution, located
between these two important residues, is completely ineffective in
transporting carnitinewhile P46S, located closer to the other asparagine
residue involved in glycosylation, retains residual transport activity and
might be responsible for a milder or no overt phenotype [5]. It is still
unclear whether carnitine supplements are warranted for patients
Fig. 8. Tunicamycin effect on carnitine transport (A), cell protein content (B), and kinetic constants for carnitine transport (C) in CHO cells overexpressing theOCTN2 carnitine transporter.
(A) Cells were incubated in 24-well plates with the indicated concentrations of tunicamycin for 24 h before the transport assay. Carnitine (0.5 μM) transport wasmeasured for 30 min at
37 °C. (B) Protein content was measured in the same wells in which carnitine transport was measured. Points are averages of 6 observations±SE. (C) Kinetic constants for carnitine
transport in cells incubated for 16 h in the absence or presence of tunicamycin were determined as in Fig. 6. Lines represent the best ﬁt of the data to a Michaelis–Menten equation.
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beneﬁts (such as capacity to sustain exercise)with initiation of therapy.
Other organic cation and anion transporters part of the SLC22
family share this large extracellular loop between transmembraneFig. 9. Subcellular distribution of normal OCTN2 carnitine transporters tagged with the green ﬂ
seeded on glass-bottomed dishes in normal medium. Cells were incubated for 16 h with the in
were visualized by confocal microscopy at 1 μm sections. Cells were labeled in vivo with Bodip
borders and intracellular structures. Images were digitally overlayed to show the location of
membrane transporters with the Golgi is seen as a yellow signal.domains 1 and 2 and glycosylation has been studied mostly in organic
anion transporters [21]. In organic anion transporters, proper
glycosylation is important for protein folding, membrane targeting,
and substrate binding [14]. Our results in OCTN2 show that the overalluorescent protein. CHO cells stably transfected with OCTN2-GFP expression vectors were
dicated concentrations of tunicamycin prior to analysis by confocal microscopy. Live cells
y-ceramide to visualize the Golgi. Phase contrast microscopy was used to deﬁne the cell
green transporters compared to the red Golgi and plasma membrane. Co-localization of
320 C.A.S. Filippo et al. / Biochimica et Biophysica Acta 1812 (2011) 312–320structure of this large extracellular domain, rather than glycosylation
itself, is the most important determinant for these important
transporter functions.
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